文献速递胸部肿瘤消化系统肿瘤妇科肿瘤

早期ctDNA化疗反应可作为总生存的潜在替代标志物

Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival.
PubMed 文献 · Eur J Cancer · 2021-04-12

该回顾性分析纳入420例结直肠癌、卵巢癌和非小细胞肺癌患者,比较ctDNA反应率与客观缓解率作为总生存替代标志物的价值。结果显示ctDNA反应与中位生存高度相关(R2=0.99),优于首次评估缓解和ORR,提示其可能作为OS的替代标志物。

要点

  • ctDNA反应率与中位生存高度相关(R2=0.99),优于ORR(R2=0.57)。
  • ctDNA在全部研究瘤种中均提供预后信息(p<0.05)。
  • 若经验证,ctDNA反应可能影响新药审批。

核心结论

  • ctDNA反应可能作为总生存的替代标志物。
  • 若经验证,可能对新药审批产生重大影响。

研究设计与样本

  • 回顾性分析,纳入420例结直肠癌、卵巢癌和非小细胞肺癌患者,分布于五个队列。
  • 患者均来自前瞻性生物标志物研究和临床试验。
  • 所有患者在治疗开始前和首次客观缓解评估时检测ctDNA。

主要发现

  • ctDNA反应率与首次评估客观缓解中度相关(R2=0.68)。
  • ctDNA反应率与ORR中度相关(R2=0.57)。
  • ctDNA在所有研究瘤种中均提供预后信息(p<0.05)。
  • ctDNA反应与中位生存高度相关(R2=0.99),优于首次评估缓解(R2=0.70)和ORR(R2=0.57)。

关键数值与推荐

  • ctDNA反应率定义为基线可测量水平转为首次客观缓解评估时不可测量水平的患者比例。
  • 采用血浆中异常肿瘤特异性甲基化DNA检测,方法包括DNA分离、亚硫酸氢盐转化和微滴数字PCR。

临床怎么用

  • 在化疗期间早期检测ctDNA反应可能有助于预后判断。
  • ctDNA反应可作为未来临床试验中评估疗效的潜在替代终点。

局限性

  • 回顾性分析设计。
  • 结果需在前瞻性研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The aim of the study was to compare ctDNA response rate and objective response rate as surrogate markers for overall survival (OS) in patients with metastatic cancer treated with chemotherapy. METHODS: The study included 420 patients distributed in five cohorts with colorectal, ovarian, and non-small cell lung cancer. It represents a retrospective analysis of patients enrolled in prospective biomarker studies and clinical trials. All patients had ctDNA measured before start of treatment and at the first evaluation of objective response. ctDNA response rate was defined as the fraction of patients converting from a measurable level at baseline to an unmeasurable level at the first evaluation of objective response. Aberrant, tumour specific, methylated DNA was measured in plasma. The method involves DNA isolation, bisulphite conversion and droplet digital PCR. The primary outcome measure was the correlation between ctDNA response rate, overall response rate (ORR) and median survival. RESULTS: There was moderate correlation between ctDNA response rate and objective response at first evaluation (R2 = 0.68). The same applied to ctDNA response rate and ORR (R2 = 0.57). ctDNA held prognostic information in all the investigated tumour types (p < 0.05). There was a high correlation between ctDNA response and median survival across the included tumour types and treatments (R2 = 0.99) clearly outperforming both response at first evaluation and ORR (R2 = 0.70 and 0.57, respectively). CONCLUSION: The results suggest that ctDNA response might serve as a surrogate marker for OS. If validated, it may have great implications on the approval of new drugs.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jakobsen A, Andersen RF, Hansen TF, et al. Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival. Eur J Cancer. 2021. PMID: 33857886. doi:10.1016/j.ejca.2021.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。